STAT+: CMS will use outcomes-based agreements in bid to help Medicaid pay for sickle cell gene therapies
STAT
JANUARY 30, 2024
In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell disease, the U.S. million, respectively, and have raised alarms over the ability of financially strapped state Medicaid programs to absorb the expense. Two therapies recently approved by health regulators cost $2.2 million and $3.1
Let's personalize your content